Advertisement

Supportive Care in Cancer

, Volume 21, Issue 9, pp 2557–2563 | Cite as

A survey of Canadian cancer patients’ perspectives on the characteristics and treatment of breakthrough pain

  • Gillian Bedard
  • Philippa HawleyEmail author
  • Liying Zhang
  • Marissa Slaven
  • Pierre Gagnon
  • Stuart Bisland
  • Margaret Bennett
  • Francois Tardif
  • Edward Chow
Original Article

Abstract

Objective

Breakthrough pain is defined as a transient exacerbation of pain that occurs spontaneously or in response to a trigger despite stable and controlled background pain. The purpose of this study was to explore Canadian patients’ awareness of and experience with breakthrough pain in cancer (BTPc).

Methods

Four Canadian cancer centers participated in a non-interventional survey recruiting cancer patients who experienced breakthrough pain. These patients were asked about their pain, its impact on functioning, current management and interest in new treatments of BTPc.

Results

Ninety-four Canadian cancer patients participated in this study, with 96 % stating that cancer pain impacted their daily living with over half unable to go to work or shopping. Fifty percent of patients said that an episode of BTPc lasted greater than 60 minutes, with the pain score being on average 7.8/10, impacting normal work (7.2/10) and general activity (7.1/10). Only 35 % of patients were very satisfied with the speed of relief of their medications. Those who did not take their breakthrough pain medication for every episode stated that was because the pain was not always severe (37 %), or they were afraid of becoming tolerant (23 %) or addicted (12 %). Patients stated that the most important features of a new treatment for BTPc were the ability to relieve pain completely (47 %), and quickly (43 %). Patients expressed willingness to try transmucosal products (80 %) or nasal products (59 %).

Conclusion

Breakthrough cancer pain in Canadian cancer patients greatly impacts their daily lives. There is room for improvement in the management of BTPc, and the majority of patients would be willing to try new treatments.

Keywords

Breakthrough pain Cancer Patients’ perspectives 

Notes

Acknowledgments

This study was funded by Takeda Canada Inc. We thank all survey participants and research assistants.

Conflict of interest

This study was funded by Takeda Canada Inc. The authors have full control of all primary data and agree to allow the journal to review their data if requested.

References

  1. 1.
    Burton AW, Fine PG, Passik SD (2012) Transformation of acute cancer pain to chronic cancer pain syndromes. J Support Oncol 10(3):89–95CrossRefGoogle Scholar
  2. 2.
    Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G (2009) Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 13(4):331–338CrossRefGoogle Scholar
  3. 3.
    Webber K, Davies AN, Cowie MR (2011) Breakthrough pain: a qualitative study involving patients with advanced cancer. Support Care Cancer 19(12):2041–2046CrossRefGoogle Scholar
  4. 4.
    Mercadante S, Ferrera P, Adile C, Casuccio A (2011) Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose. J Pain Symptom Manage 42(3):464–469CrossRefGoogle Scholar
  5. 5.
    Mercadante S (2012) Pharmacotherapy for breakthrough cancer pain. Drugs 72(2):181–190CrossRefGoogle Scholar
  6. 6.
    Radbruch L, Torres LM, Ellershaw JE, Gatti A, Luis Lerzo G, Revnic J et al (2012) Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain. Support Care Cancer 20(3):565–573CrossRefGoogle Scholar
  7. 7.
    Davies A, Zeppetella G, Andersen S, Damkier A, Vejlgaard T, Nauck F et al (2011) Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain 15(7):756–763CrossRefGoogle Scholar
  8. 8.
    Cleeland CS, Ryan KM (1994) Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 23(2):129–138PubMedGoogle Scholar
  9. 9.
    American Pain F (2011) Breakthrough cancer pain: mending the break in the continuum of care. J Pain Palliat Care Pharmacother 25(3):252–264CrossRefGoogle Scholar
  10. 10.
    Bhatnagar S, Upadhyay S, Mishra S (2010) Prevalence and characteristics of breakthrough pain in patients with head and neck cancer: a cross-sectional study. J Palliat Med 13(3):291–295CrossRefGoogle Scholar
  11. 11.
    Gomez-Batiste X, Madrid F, Moreno F, Gracia A, Trelis J, Nabal M et al (2002) Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia Spain. J Pain Symptom Manag 24(1):45–52CrossRefGoogle Scholar
  12. 12.
    Portenoy RK, Bruns D, Shoemaker B, Shoemaker SA (2010) Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 2: impact on function, mood, and quality of life. J Opioid Manag 6(2):109–116CrossRefGoogle Scholar
  13. 13.
    Portenoy RK, Hagen NA (1990) Breakthrough pain: definition, prevalence and characteristics. Pain 41(3):273–281CrossRefGoogle Scholar
  14. 14.
    Portenoy RK, Bruns D, Shoemaker B, Shoemaker SA (2010) Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 1: prevalence and characteristics. J Opioid Manag 6(2):97–108CrossRefGoogle Scholar
  15. 15.
    Davis MP (2011) Fentanyl for breakthrough pain: a systematic review. Expert Rev Neurother 11(8):1197–1216CrossRefGoogle Scholar
  16. 16.
    Rauck R, Reynolds L, Geach J, Bull J, Stearns L, Scherlis M et al (2012) Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 28(5):859–870CrossRefGoogle Scholar
  17. 17.
    Foster D, Upton R, Christrup L, Popper L (2008) Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. Ann Pharmacother 42(10):1380–1387CrossRefGoogle Scholar
  18. 18.
    Ward SE, Goldberg N, Miller-McCauley V, Mueller C, Nolan A, Pawlik-Plank D et al (1993) Patient-related barriers to management of cancer pain. Pain 52(3):319–324CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Gillian Bedard
    • 1
  • Philippa Hawley
    • 2
    • 8
    Email author
  • Liying Zhang
    • 1
  • Marissa Slaven
    • 3
  • Pierre Gagnon
    • 4
    • 5
    • 6
    • 7
  • Stuart Bisland
    • 3
  • Margaret Bennett
    • 1
  • Francois Tardif
    • 4
    • 6
  • Edward Chow
    • 1
  1. 1.Sunnybrook Health Sciences Centre, Odette Cancer CentreUniversity of TorontoTorontoCanada
  2. 2.Palliative Medicine, BC Cancer AgencyUniversity of British ColumbiaVancouverCanada
  3. 3.Palliative Care, Juravinski Cancer Center Hamilton Health Science CorporationMcMaster UniversityHamiltonCanada
  4. 4.Psycho-oncologie, Centre Hospitalier Universitaire de QuebecUniversity of QuebecQuebec CityCanada
  5. 5.Laval University Cancer Research CenterQuebec CityCanada
  6. 6.Maison Michel-SarrazinQuebec CityCanada
  7. 7.Faculty of PharmacyLaval UniversityQuebec CityCanada
  8. 8.Pain and Symptom Management/Palliative CareVancouver Centre, BC Cancer AgencyVancouverCanada

Personalised recommendations